论文部分内容阅读
目的:探讨急性冠状动脉综合征(ACS)患者外周血CD4+ CD28null T细胞和CD4+ CD28+ T细胞上电压依赖性钾离子通道(Kv1.3)和钙依赖激活的钾离子通道(IKCa1)的表达。方法:入选对象共75例,分为3组:其中ACS组27例,稳定型心绞痛组20例,对照组28例。分离外周血单个核细胞(PBMCs),用ELISA法测定PBMCs中NF-κB的活性,流式细胞仪计数CD4+ CD28nullT细胞占CD4+T细胞的比例。免疫荧光染色标记结合膜片钳技术记录ACS组CD4+ CD28null T细胞和CD4+ CD28+ T细胞上Kv1.3和IKCa1的电流,计算单细胞上通道的数目。结果:ACS组NF-κB的活性和CD4+CD28null T细胞的比例显著高于稳定型心绞痛组和对照组(P<0.05)。NF-κB的活性和CD4+ CD28null T细胞的比例具有正相关关系(r=0.369,P<0.05)。CD4+ CD28null T细胞上Kv1.3的数目和电流密度显著高于CD4+ CD28+T细胞(P<0.05)。CD4+ CD28null T细胞、CD4+ CD28+ T细胞上IKCa1的数目差异无统计学意义(P>0.05)。结论:Kv1.3通道对CD4+ CD28null T细胞的功能具有重要作用,Kv1.3通道有可能成为AS治疗的新靶点。
Objective: To investigate the expression of voltage-dependent potassium channel (Kv1.3) and calcium-dependent activated potassium channel (IKCa1) in peripheral blood CD4 + CD28null T cells and CD4 + CD28 + T cells in patients with acute coronary syndrome (ACS) Methods: A total of 75 subjects were enrolled and divided into 3 groups: 27 in ACS group, 20 in stable angina pectoris group and 28 in control group. Peripheral blood mononuclear cells (PBMCs) were isolated and the activity of NF-κB in PBMCs was measured by ELISA. The proportion of CD4 + CD28nullT cells in CD4 + T cells was counted by flow cytometry. Immunofluorescence staining and patch clamp techniques were used to record the currents of Kv1.3 and IKCa1 on CD4 + CD28null T cells and CD4 + CD28 + T cells in ACS group. Results: The activity of NF-κB and the percentage of CD4 + CD28null T cells in ACS group were significantly higher than those in stable angina pectoris group and control group (P <0.05). There was a positive correlation between the activity of NF-κB and the proportion of CD4 + CD28null T cells (r = 0.369, P <0.05). The number and current density of Kv1.3 on CD4 + CD28null T cells were significantly higher than those on CD4 + CD28 + T cells (P <0.05). The number of IKCa1 in CD4 + CD28null T cells and CD4 + CD28 + T cells showed no significant difference (P> 0.05). Conclusion: Kv1.3 channel plays an important role in the function of CD4 + CD28null T cells. Kv1.3 channel may be a new target for AS therapy.